Integration of allogeneic lymphocyte immunotherapy with short-course chemotherapy and hypoenergic hyperthermia: a "triple-threat" treatment for disseminated cancer.
A strategy for treatment of disseminated cancer is proposed which unites short-course chemotherapy, local hyperthermia, and allogeneic lymphocyte immunotherapy, designed and timed so as to optimize their synergistic interactions. Short-course chemotherapy potentiates allogeneic lymphocyte immunotherapy, and in turn is potentiated by subsequent courses of local hyperthermia. Response to hyperthermia can be enhanced by measures which selectively inhibit tumor blood flow, impair tumor energy metabolism, and produce tumor acidification; these include induction of prolonged hyperglycemia, and administration of selectively activated "hypoenergic" agents which inhibit or uncouple tumor respiration. It is anticipated that these methods will enable a significant advance in the control of metastasized solid tumors.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001786:Blood Glucose / Q000378:metabolism; D003131:Combined Modality Therapy; D004734:Energy Metabolism; D006801:Humans; D006979:Hyperthermia, Induced; D007167:Immunotherapy; D017710:Lymphocyte Transfusion; D009369:Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000628:therapy*
D000970:Antineoplastic Agents; D001786:Blood Glucose